CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Nikko Asset Management Americas Inc.

Nikko Asset Management Americas Inc. lowered its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,369,762 shares of the company's stock after selling 95,708 shares during the period. CRISPR Therapeutics comprises approximately 2.0% of Nikko Asset Management Americas Inc.'s holdings, making the stock its 13th largest position. Nikko Asset Management Americas Inc. owned about 4.24% of CRISPR Therapeutics worth $210,913,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Jump Financial LLC increased its stake in shares of CRISPR Therapeutics by 194.7% during the 3rd quarter. Jump Financial LLC now owns 33,307 shares of the company's stock worth $1,512,000 after purchasing an additional 22,006 shares in the last quarter. Invesco Ltd. increased its stake in shares of CRISPR Therapeutics by 1.5% during the 3rd quarter. Invesco Ltd. now owns 136,123 shares of the company's stock worth $6,179,000 after purchasing an additional 2,061 shares in the last quarter. ARK Investment Management LLC increased its stake in shares of CRISPR Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company's stock worth $534,360,000 after purchasing an additional 1,372,986 shares in the last quarter. Prime Capital Investment Advisors LLC purchased a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $206,000. Finally, Baker Chad R increased its stake in shares of CRISPR Therapeutics by 89.1% during the 4th quarter. Baker Chad R now owns 98,520 shares of the company's stock worth $6,167,000 after purchasing an additional 46,420 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 6,370 shares of the business's stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $507,497.90. Following the sale, the chief executive officer now owns 194,257 shares in the company, valued at $15,476,455.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 6,370 shares of the company's stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total value of $507,497.90. Following the transaction, the chief executive officer now owns 194,257 shares in the company, valued at approximately $15,476,455.19. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Raju Prasad sold 3,524 shares of the company's stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.69, for a total transaction of $256,159.56. Following the completion of the transaction, the chief financial officer now owns 6,476 shares in the company, valued at approximately $470,740.44. The disclosure for this sale can be found here. Insiders sold 63,992 shares of company stock valued at $4,525,135 in the last ninety days. Company insiders own 4.10% of the company's stock.

Analysts Set New Price Targets

CRSP has been the subject of a number of recent research reports. Cantor Fitzgerald reissued a "neutral" rating on shares of CRISPR Therapeutics in a research note on Thursday, May 9th. Needham & Company LLC decreased their price target on shares of CRISPR Therapeutics from $90.00 to $88.00 and set a "buy" rating on the stock in a report on Thursday, May 9th. Royal Bank of Canada lifted their price target on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a "sector perform" rating in a report on Thursday, February 22nd. Robert W. Baird lifted their target price on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a "neutral" rating in a report on Thursday, May 9th. Finally, Morgan Stanley lifted their target price on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an "underweight" rating in a report on Monday, February 26th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $73.93.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP traded up $0.55 during trading on Friday, reaching $56.22. 1,071,541 shares of the company's stock traded hands, compared to its average volume of 1,749,516. CRISPR Therapeutics AG has a 12 month low of $37.55 and a 12 month high of $91.10. The company has a 50 day moving average of $62.11 and a 200-day moving average of $65.21. The stock has a market capitalization of $4.77 billion, a P/E ratio of -20.67 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.08). The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $25.53 million. The firm's revenue was down 99.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.67) earnings per share. Equities research analysts predict that CRISPR Therapeutics AG will post -5.64 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.